Search - tctmd.com

Displaying 121 - 140 of 213

Sort: Relevancy | Date

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

News Daily News

Black Men Have Twofold Higher Risk of Dying From First CHD Event

Michael O'Riordan

July 10, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Daily News

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Shelley Wood

September 28, 2016

News Daily News

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Shelley Wood

September 28, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

冠脉内阿昔单抗显示对糖尿病 STEMI 患者有优势

L.A. McKeown

August 11, 2016

News Daily News

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

L.A. McKeown

August 11, 2016

News Daily News

El Abciximab Intracoronario es Beneficioso en Pacientes Diabéticos Víctimas de STEMI

L.A. McKeown

August 11, 2016

Presentation

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Presenter: Raffaele Piccolo

August 10, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

Advertisement

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Black Men Have Twofold Higher Risk of Dying From First CHD Event

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

螯合治疗：TACT2 试验为糖尿病传统 MI 后治疗提供前景

Más Quelación: Se Aprueba el Ensayo TACT2 para el Controvertido Tratamiento Post-IM en Pacientes Diabéticos

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

冠脉内阿昔单抗显示对糖尿病 STEMI 患者有优势

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

El Abciximab Intracoronario es Beneficioso en Pacientes Diabéticos Víctimas de STEMI

Intracoronary Abciximab Shows Advantage in Diabetic STEMI Patients

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content